Eli Lilly's Zepbound obesity drug covered by Medicare for sleep apnea
Portfolio Pulse from
Eli Lilly's obesity drug, Zepbound, is now covered by Medicare for obstructive sleep apnea, following its approval for this condition in December.
January 09, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Zepbound, an obesity drug, is now covered by Medicare for obstructive sleep apnea, which could lead to increased sales and market penetration.
The Medicare coverage for Zepbound in treating sleep apnea could significantly increase its market reach and sales, positively impacting Eli Lilly's financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100